Research by Li et al. found that writers (such as METTL3 and METTL14) suppress T cell functions by enhancing the expression of immune checkpoints (PD-L1) and promoting glycolysis, leading to immunotherapy resistance; meanwhile, erasers (such as FTO and ALKBH5) maintain tumor stem cell characteristics and an immunosuppressive microenvironment by lowering m6A modification levels, weakening the effects of immunotherapy. Here, FTO is linked to neoplasm.